NASDAQ: SGHTSight Sciences Inc Stock
$6.28+0.13 (+2.11%)
Updated Jan 30, 2026
SGHT Price
$6.28
Fair Value Price
N/A
Market Cap
$332.03M
52 Week Low
$2.03
52 Week High
$9.24
P/E
-6.9x
P/B
5.16x
P/S
2.37x
PEG
N/A
Dividend Yield
N/A
Revenue
$76.05M
Earnings
-$46.11M
Gross Margin
86%
Operating Margin
-53.98%
Profit Margin
-60.6%
Debt to Equity
0.81
Operating Cash Flow
-$31M
Beta
1.78
Next Earnings
Mar 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
SGHT Overview
Sight Sciences Incorporated is an ophthalmic medical device company (surgical and nonsurgical technologies for the treatment of eye diseases).The company's OMNI Surgical System is a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients. It also offers the TearCare System, a wearable eyelid technology for the treatment of dry eye disease. Sight Sciences was incorporated in 2010 and is headquartered in Menlo Park, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SGHT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
SGHT
Ranked#41 of 100
Ranked#41 of 100
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.94 | A | |
| $28.86 | A | |
| $7.93 | A |
Be the first to know about important SGHT news, forecast changes, insider trades & much more!
SGHT News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SGHT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SGHT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SGHT is poor value based on its book value relative to its share price (5.16x), compared to the US Medical Devices industry average (3.81x)
P/B vs Industry Valuation
SGHT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SGHT due diligence checks available for Premium users.
Valuation
SGHT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.9x
Industry
24.69x
Market
43.06x
SGHT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.16x
Industry
3.81x
SGHT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SGHT's financial health
Profit margin
Revenue
$19.9M
Net Income
-$8.2M
Profit Margin
-41%
SGHT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SGHT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$116.3M
Liabilities
$52.0M
Debt to equity
0.81
SGHT's short-term assets ($113.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SGHT's short-term assets ($113.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SGHT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.7M
Investing
-$170.0k
Financing
$25.0k
SGHT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SGHT vs Medical Device Stocks
Sight Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.